WO2002045659A3 - Novel therapeutics for heart failure and aging - Google Patents

Novel therapeutics for heart failure and aging Download PDF

Info

Publication number
WO2002045659A3
WO2002045659A3 PCT/US2001/051272 US0151272W WO0245659A3 WO 2002045659 A3 WO2002045659 A3 WO 2002045659A3 US 0151272 W US0151272 W US 0151272W WO 0245659 A3 WO0245659 A3 WO 0245659A3
Authority
WO
WIPO (PCT)
Prior art keywords
heart failure
nfλb
myo
aging
novel therapeutics
Prior art date
Application number
PCT/US2001/051272
Other languages
French (fr)
Other versions
WO2002045659A9 (en
WO2002045659A2 (en
Inventor
Natarajan Sivasubramanian
Pascal Knuefermann
Douglas L Mann
Original Assignee
Baylor College Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baylor College Medicine filed Critical Baylor College Medicine
Priority to AU2002239777A priority Critical patent/AU2002239777A1/en
Publication of WO2002045659A2 publication Critical patent/WO2002045659A2/en
Publication of WO2002045659A9 publication Critical patent/WO2002045659A9/en
Publication of WO2002045659A3 publication Critical patent/WO2002045659A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Myo/V1 is a cardiac-associated protein which interacts with NFλB, a well known stress-responsive cytoprotective transcription factor. Myo/V1 is upregulated during cardiac hypertrophy and heart failure. The present invention is directed to the function of Myo/V1 disruption of NFλB activity by promoting the formation of NFλB p50-p50 homodimers or p65-p65 homodimers, which results in altered adrenergic singlaing during these events.
PCT/US2001/051272 2000-10-27 2001-10-26 Novel therapeutics for heart failure and aging WO2002045659A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002239777A AU2002239777A1 (en) 2000-10-27 2001-10-26 Novel therapeutics for heart failure and aging

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24398500P 2000-10-27 2000-10-27
US60/243,985 2000-10-27

Publications (3)

Publication Number Publication Date
WO2002045659A2 WO2002045659A2 (en) 2002-06-13
WO2002045659A9 WO2002045659A9 (en) 2003-08-07
WO2002045659A3 true WO2002045659A3 (en) 2005-04-07

Family

ID=22920925

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/051272 WO2002045659A2 (en) 2000-10-27 2001-10-26 Novel therapeutics for heart failure and aging

Country Status (2)

Country Link
AU (1) AU2002239777A1 (en)
WO (1) WO2002045659A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005056020A2 (en) * 2003-12-02 2005-06-23 Corgentech, Inc. Nf-kb oligonucleotide decoy molecules
JP6782716B2 (en) * 2015-06-25 2020-11-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Cell-based assay to reveal antibody or ligand binding and function

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284932A (en) * 1990-09-07 1994-02-08 The Cleveland Clinic Foundation Process for purifying and characterizing myotrophia, a novel peptide that regulates myocardial growth
US6153423A (en) * 1997-09-19 2000-11-28 Incyte Pharmaceuticals, Inc. Human myotrophin

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5284932A (en) * 1990-09-07 1994-02-08 The Cleveland Clinic Foundation Process for purifying and characterizing myotrophia, a novel peptide that regulates myocardial growth
US6153423A (en) * 1997-09-19 2000-11-28 Incyte Pharmaceuticals, Inc. Human myotrophin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDERSON K.M. ET AL.: "cDNA sequence and characterization of the gene that encodes human myotrophin/V-1 protein, a mediator of cardiac hypertrophy", JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, vol. 31, 1999, pages 705 - 719, XP002984353 *
LOGEAT F. ET AL.: "Inhibition of transcription factors belonging to the rel/NF-kappaB family by a transdominant negative mutant", THE EMBO JOURNAL, vol. 10, no. 7, 1991, pages 1827 - 1832, XP008043412 *

Also Published As

Publication number Publication date
WO2002045659A9 (en) 2003-08-07
WO2002045659A2 (en) 2002-06-13
AU2002239777A1 (en) 2002-06-18

Similar Documents

Publication Publication Date Title
UA94399C2 (en) Mutant promoters aox1
WO2003080801A3 (en) Adipose stromal stem cells for tissue and vascular modification
EP1180371A4 (en) Agents promoting the formation of skin basement membrane, agents promoting the formation of artificial skin and process for producing artificial skin
WO2001079460A3 (en) Polypeptides having haloperoxidase activity
WO2006019668A3 (en) (1s,5s)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
ATE410998T1 (en) USE OF A PROTEIN KINASE A INACTIVATIVE COMPOUND IN A COSMETICALLY ACCEPTABLE COMPOSITION FOR SKIN LIGHTENING
WO2003094856A3 (en) 1l1rl-1 as a cardiovascular disease marker and therapeutic target
WO2005099756A3 (en) ErbB ANTAGONISTS FOR PAIN THERAPY
WO1999065913A3 (en) Epothilone minor constituents
WO2002057290A3 (en) Novel fibronectin epitopes and proteinaceous molecules capable of binding said epitopes
WO2006127152A3 (en) Methods for making and using regulatory t cells
WO2004053101A3 (en) Methods and compositions using compounds from fetal cells and tissues to improve condition of skin
EP1760115A4 (en) Composition and method for producing same
WO2002034233A3 (en) Use of an association of a carotenoid and of an isoflavonoid for treating cutaneous symptoms of ageing
WO2002045659A3 (en) Novel therapeutics for heart failure and aging
WO2004113528A3 (en) Isoforms of elf-5a: senescence-induced elf5a; wounding-induced elf-5a; growth elf-5a; and dhs
TW200603824A (en) Prostaglandin reductase
WO2006040685A3 (en) Methods for improving tree growth and wood properties
WO2003065046A3 (en) Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor
WO2004033645A3 (en) Methods of regulating body weight
WO2002064179A8 (en) Bioartificial primarily vascularized tissue matrix, bioartificial primarily vascularized tissue, method for the production thereof and use of the same
WO2001072328A3 (en) Methods of treating diseases with activated protein c
WO2002012887A3 (en) Methods and compositions for the diagnosis and treatment of brown adipose cell disorders
WO2006015103A3 (en) Crane bearing assembly
AU2002241277A1 (en) Functional plant, promoter to be used for producing the functional plant and method of using the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

121 Ep: the epo has been informed by wipo that ep was designated in this application
COP Corrected version of pamphlet

Free format text: PAGES 1/43-43/43, DRAWINGS, REPLACED BY NEW PAGES 1/44-44/44; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

122 Ep: pct application non-entry in european phase
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
NENP Non-entry into the national phase

Ref country code: JP